MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12931-026-03656-9

Медицинская библиотека · Respiratory research · 2026

Tracking the evolution of biomarker efficacy in SARS-CoV-2: a global meta-analyses series.

Shuvo Me Rahman, Schwiening Max, Avramidis Nikos, Soares Felipe, Feng Oliver, Abreu Susana, Veale Niki, Thomas William, Thompson A A Roger, Samworth Richard J, Morrell Nicholas W, Semple Malcolm G, Baillie Kenneth, Marciniak Stefan J, Soon Elaine

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Sophisticated prognostic scores have been proposed for SARS-CoV-2 but do not always perform consistently. We performed this systematic review to discover why and to investigate the impact of vaccination and viral variants.

METHODS

We searched the PubMed database for the keywords ‘SARS-CoV-2’ or ‘Covid19’ with ‘biomarker’ and ‘mortality’ for the baseline tranche (01/12/2019–30/06/2021) and either ‘SARS-CoV-2’ or ‘Covid19’ with ‘biomarker’ and either ‘vaccination’ or ‘variant’ from 01/12/2020 to 31/10/2023. To aggregate the data, the meta library in R was used, and a random effects model fitted to obtain pooled AUCs and 95% confidence intervals.

RESULTS

We screened 4,688 potential source manuscripts and included 144 in the final analyses. Biomarker effectiveness varies significantly by geographical region. Admission CRP levels were a good prognostic marker for mortality due to wild-type virus in Asian countries, with a pooled area under curve (AUC) of 0.83 (95%CI 0.80–0.85), but only an average predictor of mortality in Europe/Northern America, with a pooled AUC of 0.67 (95%CI 0.63–0.71, P < 0.0001). The same pattern applies to D-dimer and IL-6. Notably, urea and troponin had pooled AUCs ≥ 0.78 regardless of location, implying that end-organ damage at presentation was a key prognostic factor in wild-type SARS-CoV-2 infection. CRP, D-dimer, and IL-6 have generally declined in effectiveness in the vaccinated and variant cohorts. We note a significant lag from the pandemic advent to data availability and that the type of data varied considerably between studies.

CONCLUSION

Biomarkers and prognostic scores should be tailored to populations. It is imperative that the infrastructure for collecting clinical data should be put in place ahead of a future pandemic so that data harvesting, collation and analysis can occur in a robust and timely manner to aid clinical decision making.

TRIAL REGISTRATION: This study was registered with PROSPERO (CRD42022366893).

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-026-03656-9.

Для цитирования: Shuvo Me Rahman, Schwiening Max, Avramidis Nikos, Soares Felipe, Feng Oliver, Abreu Susana, Veale Niki, Thomas William, Thompson A A Roger, Samworth Richard J, Morrell Nicholas W, Semple Malcolm G, Baillie Kenneth, Marciniak Stefan J, Soon Elaine. Tracking the evolution of biomarker efficacy in SARS-CoV-2: a global meta-analyses series.. Respiratory research. 2026. DOI: 10.1186/s12931-026-03656-9.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.